CYP2C19 rs6759892: Understanding This Genetic Variant
The rs6759892 variant is a genetic marker located within the CYP2C19 gene, which provides instructions for making an enzyme responsible for breaking down many common medications. Variations in this gene can influence how efficiently your body processes drugs like clopidogrel, voriconazole, and certain antidepressants.
What each genotype means
Typical baseline CYP2C19 function
You carry two copies of the reference G allele at rs6759892, meaning you do not have the CYP2C19*6 loss-of-function variation at this specific site. In clinical studies, this genotype does not cause a reduction in CYP2C19 enzyme activity by itself. However, your overall metabolism of medications such as clopidogrel, escitalopram, or voriconazole also depends on other CYP2C19 alleles, so discuss your complete pharmacogenomic results and dosing with your clinician or pharmacist.
Carried by more than 99% of individuals across all major global ancestries.
One non-functional copy detected
You carry one copy of the rare A allele at rs6759892, which defines the non-functional CYP2C19*6 allele. In research and pharmacogenomic guidelines, carrying one non-functional allele typically reduces your capacity to metabolize CYP2C19 substrate medications, potentially categorizing you as an intermediate metabolizer depending on your other chromosome. Always discuss medication choices and dosing adjustments for drugs such as clopidogrel or antidepressants with your clinician or pharmacist.
Found in approximately 1 in 300 to 1 in 500 people globally, reaching roughly 0.6% in East Asian populations.
Loss-of-function poor metabolizer
You carry two copies of the A allele at rs6759892, which corresponds to the homozygous CYP2C19*6/*6 diplotype. Published pharmacogenomic guidelines classify this profile as resulting in a complete lack of functional CYP2C19 enzyme activity, creating a poor metabolizer phenotype with altered activation or clearance of drugs like clopidogrel and voriconazole. Because this significantly changes medication response, speak with your clinician or pharmacist before initiating or altering any drug therapies.
Extremely rare across all ancestral groups, occurring in fewer than 1 in 100,000 individuals worldwide.
What is rs6759892 and Where is it Located?
The rs6759892 variant is a specific single nucleotide polymorphism (SNP) found within the CYP2C19 gene. This gene is located on chromosome 10 and encodes the cytochrome P450 2C19 enzyme. This enzyme is a member of the cytochrome P450 superfamily, a group of proteins primarily responsible for the metabolism of a wide array of substances, including endogenous compounds and exogenous drugs. While the human genome contains thousands of SNPs, rs6759892 is of particular interest in the field of pharmacogenomics—the study of how genes affect a person's response to drugs. By identifying specific variations at this location, researchers aim to understand why individuals may experience different therapeutic effects or side effects when taking the same medication at the same dose.
The Role of the CYP2C19 Gene
The CYP2C19 enzyme plays a critical role in the liver by metabolizing approximately 10% of clinically used drugs. It is responsible for either activating prodrugs—medications that must be converted into their active form to work—or breaking down active drugs so they can be cleared from the body. For example, the antiplatelet medication clopidogrel requires activation by CYP2C19 to prevent blood clots. If an individual carries genetic variants that reduce the function of this enzyme, they may not convert enough of the drug into its active form, potentially leading to reduced efficacy. Conversely, for drugs that are deactivated by the enzyme, reduced function could lead to higher drug levels in the blood, increasing the risk of toxicity. Understanding your genetic profile for this gene can help clinicians make more informed decisions regarding medication selection and dosing.
Research Associations and Evidence Strength
Research into CYP2C19 variants is extensive, though the evidence strength for specific SNPs like rs6759892 can vary. Many studies have established that loss-of-function alleles in CYP2C19 are associated with poor metabolism of drugs such as clopidogrel, voriconazole, and escitalopram. While some variants are well-characterized, the clinical impact of others is still being investigated. It is important to note that genetic testing is only one piece of the puzzle; other factors such as age, liver function, drug-drug interactions, and overall health also significantly influence how your body processes medication. Current research continues to evaluate the clinical utility of genotype-guided therapy, particularly in cardiology and psychiatry, to determine if tailoring prescriptions based on genetic data improves patient outcomes compared to standard dosing practices.
Population Frequency
The frequency of genetic variants in the CYP2C19 gene varies significantly across different ancestral populations. While some variants are relatively common in certain groups, others are rare. For rs6759892 specifically, the minor allele frequency is approximately 0.001 in global populations, though it is observed more frequently in East Asian populations at roughly 0.003. Because these frequencies differ, the likelihood of carrying a specific genotype depends heavily on your genetic ancestry. Large-scale genomic databases like gnomAD provide these frequency estimates, which help researchers understand the distribution of these variants worldwide. If you are interested in your own genetic status, it is best to consult with a healthcare provider or a genetic counselor who can interpret your results in the context of your personal and family medical history.
What You Can Do With This Information
If you have received information about your CYP2C19 genotype, it is essential to use it as a tool for conversation with your healthcare provider. You should never change your medication dosage or stop taking a prescribed drug based on genetic information without professional medical guidance. A doctor or pharmacist can evaluate your specific genotype alongside your current medications to determine if a dosage adjustment or an alternative therapy is appropriate. Genetic testing for pharmacogenomics is not a diagnostic tool for disease, but rather a way to personalize treatment plans. Keep your healthcare team informed about any genetic testing you have undergone, as this information can be a valuable part of your long-term health record and help ensure your treatments are as safe and effective as possible.
How common is this variant?
The rs6759892 variant has a minor allele frequency of approximately 0.001 globally, with a slightly higher prevalence in East Asian populations at about 0.003.
Frequently asked questions
Does having a CYP2C19 variant mean I am allergic to my medication?
No, a genetic variant in CYP2C19 does not mean you are allergic to a medication. Instead, it suggests that your body may process the drug differently, which could affect how well the drug works or increase the risk of side effects.
Should I get tested for CYP2C19 variants?
Genetic testing for CYP2C19 is typically recommended by healthcare providers only when it is clinically relevant to a specific medication you are prescribed. You should discuss the necessity and potential benefits of such testing with your doctor.
Can I change my medication dose based on my genotype?
You should never change your medication dose on your own. Any adjustments to your treatment plan must be made by your prescribing physician or pharmacist after they have reviewed your genetic results and clinical status.
Are all CYP2C19 variants the same?
No, there are many different variants within the CYP2C19 gene, and they can have very different effects on enzyme function. Some variants may decrease enzyme activity, while others may have little to no impact.
Sources & further reading
Educational information only, last refreshed 10/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6759892?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2C19
The CYP2C19*2 loss-of-function splicing defect results in impaired biotransformation of prodrugs including clopidogrel and altered clearance of proton pump inhibitors and select antidepressants.
Defines the CYP2C19*17 increased function allele, conferring rapid or ultrarapid metabolism for CPIC-actionable drugs including clopidogrel, PPIs, and SSRIs.
Variant in the CYP2C19 locus associated with altered metabolism of clopidogrel and proton-pump inhibitors.
Defines the CYP2C19*8 loss-of-function variant (c.358T>C, p.Trp120Arg) which results in no enzymatic activity and impaired metabolism of CYP2C19 substrates.
Defines the non-functional CYP2C19*3 null allele resulting from a premature stop codon, leading to poor metabolism of drugs such as clopidogrel, escitalopram, and proton pump inhibitors.
Defines the CYP2C19*4 allele caused by an ATG start codon alteration that abolishes translation, resulting in reduced or absent drug metabolism capacity.